BC Extra | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

Four companies led by Reata raised over $600 million in follow-ons ahead of Thursday’s trading session, but even with the bolus of funding this year’s follow-ons lag last year’s pace. A fifth company, Halozyme Therapeutics...
BC Extra | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BC Extra | Oct 14, 2019
Clinical News

Reata’s pivotal data in Friedreich ataxia point to submissions

Days after regaining worldwide rights to omaveloxolone, Reata announced plans to submit regulatory applications in the U.S. and other territories for the compound in Friedreich ataxia based on newly released pivotal trial data. Reata Pharmaceuticals...
BC Extra | Oct 10, 2019
Company News

On eve of pivotal data, Reata pays AbbVie $330M to regain cardiorenal candidates

With AbbVie having turned away from cardiovascular and renal indications, Reata reacquired rights to bardoxolone and second-generation NRF2 activators from its long-standing partner for $330 million in cash ahead of upcoming pivotal readouts for two...
BC Innovations | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
BC Extra | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
BC Innovations | Jun 26, 2019
Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Inducers of NFE2L2 activity could help treat AD. Postmortem brain tissue from seven AD patients had lower NFE2L2 protein levels than tissue from seven control donors, and low...
BC Extra | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data  Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BC Week In Review | Oct 12, 2018
Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
Items per page:
1 - 10 of 227